CORPORATE OFFICERS Craig R. Smith, M.D. Chairman of the Board, President and Chief Executive Officer John P. Brennan Senior Vice President, Technical Operations and General Manager, Drug Delivery Business Andrew R. Jordan Senior Vice President, Chief Financial Officer and Treasurer Nicholas Landekic Vice President, Business Development Thomas C. Seoh Vice President, General Counsel and Secretary Peter D. Suzdak, Ph.D. Senior Vice President, Research and Development William C. Vincek, Ph.D. Vice President, Corporate Quality BOARD OF DIRECTORS Craig R. Smith, M.D. Chairman of the Board, President and Chief Executive Officer George L. Bunting, Jr. President and Chief Executive Officer Bunting Management Group Richard L. Casey President and Chief Executive Officer Scios Inc. (retired) Elizabeth M. Greetham Portfolio Manager, Life Sciences Fund Weiss, Peck & Greer Investments Joseph Klein, III Healthcare Analyst The Kaufmann Fund Solomon H. Snyder, M.D. Director, Department of Neuroscience The Johns Hopkins University School of Medicine W. Leigh Thompson, M.D., Ph.D. Chairman and Chief Executive Officer Profound Quality Resources PC		STOCKHOLDER INFORMATION Corporate Headquarters Guilford Pharmaceuticals Inc. 6611 Tributary Street Baltimore, Maryland 21224 Phone: (410) 631-6300 Fax: (410) 631-6338 Independent Auditors KPMG LLP Princeton, New Jersey Legal Counsel Hogan & Hartson LLP Baltimore, Maryland Registrar and Transfer Agent American Stock Transfer & Trust Co. 40 Wall Street, 46th Floor New York, NY 10005 Common Stock Listed on NASDAQ: ‘GLFD’ Annual Meeting of Stockholders Tuesday, May 18, 1999 at 10:00 a.m. Center Club 100 Light Street Baltimore, Maryland Stock Description and Form 10-K Our common stock is listed on the Nasdaq Stock Market under the symbol ‘GLFD.’ As of March 16, 1999, we had approximately 192 holders of record of our common stock and in excess of 400 beneficial holders. We have never declared or paid any cash dividends and do not intend to do so for the foreseeable future. The following table sets forth the range of high and low sale prices for our common stock as reported on the Nasdaq Stock Market for the periods indicated below. Shareholder Inquiries Information about the Company can be obtained by contacting Guilford’s investor relations department at (410) 631-6300 or through our website at www.guilfordpharm.com. Stockholders may obtain, at no charge, a copy of the Guilford Pharmaceuticals Inc. Form 10-K, filed with the Securities and Exchange Commission, by writing to: Guilford Pharmaceuticals Inc. Investor Relations 6611 Tributary Street Baltimore, Maryland 21224
	High Low High Low 1996 1998 First Quarter  $ 17.17  $ 10.17       First Quarter  $ 24.88  $ 17.50 Second Quarter 25.17 13.33 Second Quarter 24.00 17.00 Third Quarter 20.50 11.00 Third Quarter 18.25 11.63 Fourth Quarter 23.38 16.00 Fourth Quarter 8.88 11.19 High Low High Low 1997 1999 First Quarter $ 30.25 $ 20.50 First Quarter $ 5.13 $ 10.00 Second Quarter 27.75 19.75 (through 3/16/99) Third Quarter 31.63 20.50 Fourth Quarter 32.25 17.88